Halofuginone, a promising drug for treatment of pulmonary hypertension.

Pritesh P JainTengteng ZhaoMingmei XiongShanshan SongNing LaiQiuyu ZhengJiyuan ChenShane G CarrAleksandra BabichevaAmin IzadiMarisela RodriguezShamin RahimiFrancesca BalistrieriShayan RahimiTatum SimonsonDaniela Valdez-JassoPatricia A ThistlethwaiteJohn Y-J ShyyJian WangAyako MakinoJason X-J Yuan

Published in: British journal of pharmacology (2021)

Halofuginone is a potent pulmonary vasodilator by activating Kv channels and blocking VDCC and receptor-operated and store-operated Ca2+ channels in PASMCs. The therapeutic effect of halofuginone on experimental PH is probably due to combination of its vasodilator effects, via inhibition of excitation-contraction coupling and anti-proliferative effects, via inhibition of the PI3K/Akt/mTOR signalling pathway.

Keyphrases

pulmonary hypertension
pulmonary artery
signaling pathway
pulmonary arterial hypertension
emergency department
magnetic resonance imaging
coronary artery
drug induced
anti inflammatory
quantum dots
protein kinase
energy transfer